Morepen Laboratories reported a record consolidated quarterly revenue of ₹570.13 crore in Q1FY27, accompanied by a 394% year-on-year surge in net profit after tax (PAT) to ₹56.40 crore. The Board of Directors, meeting on August 4, 2026, approved these unaudited standalone and consolidated financial results alongside key corporate governance updates, including the re-appointment of Chairman & Managing Director Sushil Suri for another three-year term. The Board also fixed September 19, 2026, as the record date for the final dividend for FY26, pending shareholder approval at the forthcoming Annual General Meeting (AGM). This performance underscores the company’s accelerating transition from commodity manufacturing to high-margin Contract Development and Manufacturing Organization (CDMO) services.

The financial turnaround is anchored by the commercial validation of its CDMO business. Morepen announced that an ₹825 crore CDMO mandate has entered the commercial supply phase, with ₹58 crore in commercial dispatches completed during the quarter. This shift towards long-duration customer programs is replacing transactional volatility with recurring revenues and higher margins. Simultaneously, the core Active Pharmaceutical Ingredient (API) franchise stabilized, posting 31% growth supported by better product mix and operating discipline. Export revenue also accelerated, rising 111% year-on-year due to prioritized customer mix strategies.

Financial Performance Highlights

*Note: EBITDA figures derived from operational highlights provided in management commentary.

Beyond pharmaceuticals, the medical devices segment contributed to diversified growth, expanding by 19%. The company maintains a scalable healthcare platform with an installed base of 20 million blood glucose meters and annual strip sales of 500 million units. This recurring consumables engine provides margin visibility alongside the company’s broader portfolio upgrade toward premium devices and Continuous Glucose Monitoring (CGM) systems.

Corporate Governance and Strategic Moves

In addition to approving the financial results, the Board addressed key corporate governance matters. The Board proposed the re-appointment of Sushil Suri as Chairman & Managing Director for a further three-year term, effective from October 20, 2026, to October 19, 2029. This appointment is subject to shareholder approval at the 41st AGM, scheduled for September 26, 2026. Furthermore, the Board sought approval to extend the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited (formerly Morepen Medtech Limited), a subsidiary, via a slump sale basis. These structural adjustments aim to streamline operations and focus core competencies.

What the Numbers Show

The divergence between revenue growth (+34%) and EBITDA expansion (+207%) indicates substantial structural improvement in cost efficiency rather than mere volume gains. With PAT growing at 394%, the company is successfully leveraging fixed costs across higher-margin CDMO contracts. The stabilization of the API business, previously characterized by volatile earnings, now supports predictable cash flows, while the new CDMO layer offers scalable upside without proportional increases in overheads. Looking ahead, Morepen has outlined a four-phase capacity augmentation roadmap to meet global demand, increasing manufacturing capacity from 535 kiloliters in Q4FY26 to 1,200 KL by FY30.

Morepen Laboratories reported a consolidated net profit of ₹563M for Q1FY26, a sharp increase compared to ₹114M in the same period last year. The pharmaceutical company's revenue from operations grew to ₹5.7B from ₹4.2B year-on-year, driven by higher sales volumes and improved operational efficiency. EBITDA surged to ₹825M from ₹242M, with EBITDA margin expanding significantly to 14.5% from 5.68%, reflecting strong operational leverage and cost discipline. This robust financial performance underscores the company's recovery trajectory and sustained demand for its product portfolio.

The Board of Directors approved the unaudited standalone and consolidated financial results during its meeting held on August 4, 2026. Statutory auditors S.P. Babuta & Associates conducted a limited review of the results in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also set September 19, 2026, as the record date for determining shareholders eligible to receive the final dividend for FY26, subject to approval at the upcoming Annual General Meeting.

Financial Performance Highlights

The latest quarterly results reflect broad-based improvement across key financial metrics. Consolidated revenue from operations rose to ₹5,701.28 lakh in Q1FY26, compared to ₹4,252.39 lakh in the same period last year. Standalone revenue grew 38% to ₹5,410.41 lakh from ₹3,912.84 lakh. Profit before tax surged to ₹745.27 lakh (consolidated) from ₹155.16 lakh, reflecting effective cost management despite rising input costs. Earnings per share increased to ₹1.03 from ₹0.20 in Q1FY25.

Selling and distribution expenses increased to ₹533.14 lakh from ₹303.96 lakh, indicating aggressive market expansion efforts. Employee benefits expense rose to ₹624.44 lakh, up from ₹552.37 lakh, reflecting inflationary adjustments and hiring activities. Finance costs remained controlled at ₹48.41 lakh.

Key Board Resolutions

Beyond financial results, the Board approved several strategic initiatives requiring shareholder approval at the 41st AGM scheduled for September 26, 2026. These include the re-appointment of Mr. Sushil Suri as Chairman & Managing Director for a three-year term from October 20, 2026, to October 19, 2029. Suri, a Chartered Accountant with over 30 years in the pharmaceutical industry, succeeds himself following the completion of his previous tenure.

The Board also proposed extending the timeline for hiving off the Medical Devices Business into Morepen Medipath Limited (formerly Morepen Medtech Limited), a subsidiary, via slump sale. This material related-party transaction aims to streamline operations and focus core resources on pharmaceuticals. The AGM will be conducted through video conferencing or other audio-visual means, as permitted by Ministry of Corporate Affairs circulars.

What the Numbers Show

The disproportionate rise in net profit and EBITDA relative to revenue growth signals significant margin improvement. While revenue grew year-on-year, EBITDA nearly tripled and EBITDA margin expanded from 5.68% to 14.5%, indicating favorable product mix shifts or successful cost containment. The increase in selling and distribution expenses outpacing revenue growth warrants monitoring, as it may pressure margins if not accompanied by proportional sales gains in subsequent periods. The absence of exceptional items in Q1FY26 highlights that current profitability is operationally driven rather than reliant on one-off gains.